Intravitreal Avacincaptad Pegol in Geographic Atrophy: Post-Hoc Analysis of Vision Loss From the GATHER Clinical Program

Related

• 

  Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

  Rishi P. Singh, MD

  Annual Meeting Talks

  2024

• 

  Dual Anti-platelet Therapy Decelerates the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

  Yodpong Chantarasorn, MD

  On Demand Cases, Courses, and Papers

  2021

• 

  Expert Panel: Socioeconomics

  Linda A. Lam, MD, MBA, FASRS

  Ella H Leung, MD

  Mohsin H. Ali, MD

  Hasenin Al-khersan, MD

  Miguel A. Busquets, MD, FACS

  Annual Meeting Talks

  2024